USNA · Usana Health Sciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $250.22M | $213.67M | $235.85M | $249.54M | - | $200.22M | $212.87M | $227.80M | - | $213.37M |
| Cost of Revenue | $59.44M | $48.81M | $50.18M | $52.45M | - | $39.26M | $40.33M | $43.07M | - | $42.53M |
| Gross Profit | $190.78M | $164.85M | $185.66M | $197.09M | - | $160.96M | $172.54M | $184.73M | - | $170.84M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $88.25M | $85.95M | $81.91M | $91.44M | - | $61.30M | $64.33M | $64.30M | - | $63.30M |
| Total Operating Expenses | $176.91M | $163.63M | $168.95M | $181.42M | - | $145.36M | $154.70M | $160.06M | - | $153.23M |
| D&A | $8.28M | $3.57M | $3.81M | $8.34M | - | - | - | $3.16M | - | - |
| Operating Income | $13.87M | $1.22M | $16.72M | $15.67M | - | $15.60M | $17.84M | $24.67M | - | $17.61M |
| Interest Expense | $240.0K | $49.0K | $259.0K | $411.0K | - | $49.0K | $43.0K | $52.0K | - | $43.0K |
| Income Tax | $8.51M | $8.46M | $8.37M | $7.45M | - | $8.00M | $9.77M | $10.57M | - | $9.18M |
| Net Income | $7.51M | ($6.52M) | $9.65M | $9.40M | - | $10.61M | $10.43M | $16.54M | - | $11.35M |
| EPS - Basic | $0.41 | ($0.36) | $0.52 | $0.49 | - | $0.56 | $0.55 | $0.86 | - | $0.59 |
| EPS - Diluted | $0.41 | ($0.36) | $0.52 | $0.49 | - | $0.56 | $0.54 | $0.86 | - | $0.59 |
Balance Sheet
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $162.75M | $145.35M | $151.34M | $179.61M | $181.77M | $364.89M | $332.42M | $328.34M | $330.42M | $307.08M |
| Accounts Receivable | $4.29M | - | - | - | - | - | - | - | - | - |
| Inventory | $96.36M | $90.78M | $83.27M | $73.56M | $69.73M | $63.98M | $61.83M | $60.87M | $61.45M | $60.08M |
| Accounts Payable | $16.23M | $16.22M | $17.90M | $13.97M | $11.98M | $7.04M | $6.65M | $8.27M | $10.07M | $9.32M |
| Current Assets | $294.23M | $264.06M | $261.87M | $281.39M | $279.19M | $451.19M | $419.08M | $421.07M | $417.75M | $390.46M |
| Total Assets | $738.97M | $726.59M | $734.53M | $746.60M | $748.19M | $671.31M | $631.42M | $629.27M | $632.76M | $601.15M |
| Current Liabilities | $117.24M | $118.66M | $121.63M | $137.38M | $139.63M | $114.78M | $103.90M | $112.63M | $118.84M | $112.56M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $144.18M | $145.04M | $148.97M | $162.72M | $161.86M | - | - | - | $135.56M | - |
| Stockholders' Equity | $543.55M | $528.07M | $531.06M | $529.76M | $532.11M | $533.09M | $512.21M | $499.99M | $497.20M | $470.39M |
| Retained Earnings | $473.24M | $467.50M | $474.02M | $477.63M | $478.94M | $474.49M | $463.88M | $453.45M | $445.22M | $428.45M |
Cash Flow
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $9.76M | - | - | $15.48M | - | - | - | $17.68M | - | - |
| Investing Cash Flow | ($2.60M) | - | - | ($3.88M) | - | - | - | ($4.07M) | - | - |
| Financing Cash Flow | ($3.64M) | - | - | ($14.47M) | - | - | - | ($11.95M) | - | - |
| CapEx | $2.65M | - | - | $2.80M | - | - | - | $3.20M | - | - |
| Free Cash Flow | $7.11M | - | - | $12.68M | - | - | - | $14.48M | - | - |
Ratios
| Metric | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 76.2% | 77.2% | 78.7% | 79.0% | - | 80.4% | 81.1% | 81.1% | - | 80.1% |
| Operating margin | 5.5% | 0.6% | 7.1% | 6.3% | - | 7.8% | 8.4% | 10.8% | - | 8.3% |
| EBITDA margin | 8.9% | 2.2% | 8.7% | 9.6% | - | - | - | 12.2% | - | - |
| Net margin | 3.0% | -3.1% | 4.1% | 3.8% | - | 5.3% | 4.9% | 7.3% | - | 5.3% |
| Free cash flow margin | 2.8% | - | - | 5.1% | - | - | - | 6.4% | - | - |
| FCF / Net income | 0.95 | - | - | 1.35 | - | - | - | 0.88 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 35.3% | 40.2% | 34.7% | 36.6% | - | 30.6% | 30.2% | 28.2% | - | 29.7% |
| Effective tax rate | 53.1% | 437.2% | 46.4% | 44.2% | - | 43.0% | 48.4% | 39.0% | - | 44.7% |
| Return on assets | 1.0% | -0.9% | 1.3% | 1.3% | - | 1.6% | 1.7% | 2.6% | - | 1.9% |
| Return on equity | 1.4% | -1.2% | 1.8% | 1.8% | - | 2.0% | 2.0% | 3.3% | - | 2.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.51 | 2.23 | 2.15 | 2.05 | 2.00 | 3.93 | 4.03 | 3.74 | 3.52 | 3.47 |
| Quick ratio | 1.69 | 1.46 | 1.47 | 1.51 | 1.50 | 3.37 | 3.44 | 3.20 | 3.00 | 2.94 |
| Cash ratio | 1.39 | 1.22 | 1.24 | 1.31 | 1.30 | 3.18 | 3.20 | 2.92 | 2.78 | 2.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 57.8x | 25.0x | 64.5x | 38.1x | - | 318.4x | 414.9x | 474.5x | - | 409.5x |
| Equity multiplier | 1.36 | 1.38 | 1.38 | 1.41 | 1.41 | 1.26 | 1.23 | 1.26 | 1.27 | 1.28 |
| Liabilities / Assets | 0.20 | 0.20 | 0.20 | 0.22 | 0.22 | - | - | - | 0.21 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.34 | 0.29 | 0.32 | 0.33 | - | 0.30 | 0.34 | 0.36 | - | 0.35 |
| Inventory turnover | 0.62 | 0.54 | 0.60 | 0.71 | - | 0.61 | 0.65 | 0.71 | - | 0.71 |
| Days sales outstanding | 6d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 592d | 679d | 606d | 512d | - | 595d | 560d | 516d | - | 516d |
| Days payable outstanding | 100d | 121d | 130d | 97d | - | 65d | 60d | 70d | - | 80d |
| Cash conversion cycle | 498d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 41.2x | - | 59.9x | 56.7x | - | 67.7x | 83.8x | 56.4x | - | 99.3x |
| P / B | 0.6x | 1.0x | 1.1x | 1.0x | - | 1.4x | 1.7x | 1.9x | - | 2.4x |
| P / S | 1.2x | 2.4x | 2.4x | 2.1x | - | 3.6x | 4.1x | 4.1x | - | 5.3x |
| EV / EBITDA | 6.7x | 78.6x | 20.7x | 14.6x | - | - | - | 21.8x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.3% | 6.7% | 10.8% | 9.5% | - | -6.2% | -10.6% | -8.3% | - | -8.5% |
| Revenue CAGR (3y) | 0.2% | -2.9% | -3.7% | -2.9% | - | - | - | -9.6% | - | -10.6% |
| Revenue CAGR (5y) | -4.1% | -6.5% | -1.9% | -1.3% | - | -5.1% | -3.6% | -3.6% | - | -6.4% |
| Gross profit growth (YoY) | -3.2% | 2.4% | 7.6% | 6.7% | - | -5.8% | -11.5% | -7.6% | - | -8.5% |
| Operating income growth (YoY) | -11.5% | -92.2% | -6.3% | -36.5% | - | -11.4% | -26.9% | -8.1% | - | -22.2% |
| Net income growth (YoY) | -20.1% | - | -7.4% | -43.1% | - | -6.5% | -39.7% | -10.0% | - | -24.0% |
| EPS growth (YoY) | -16.3% | - | -3.7% | -43.0% | - | -5.1% | -39.3% | -9.5% | - | -24.4% |
| EPS CAGR (3y) | -24.4% | - | -34.7% | -24.8% | - | - | - | -16.0% | - | -25.7% |
| EPS CAGR (5y) | -22.3% | - | -17.0% | -16.8% | - | -12.5% | -9.9% | -3.2% | - | -13.8% |
| FCF growth (YoY) | -43.9% | - | - | -12.4% | - | - | - | 35.0% | - | - |
| FCF CAGR (5y) | -17.0% | - | - | -11.6% | - | - | - | 37.5% | - | - |
| Book value growth (YoY) | 2.6% | -0.9% | 3.7% | 6.0% | 7.0% | 13.3% | 9.3% | 9.8% | 14.4% | 14.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-01-03.
Business segments
$925.26M totalCore Nutritional$775.45M · 83.8%
Hiya$131.97M · 14.3%
All Other$17.83M · 1.9%
Geographic
$2.23B totalAsia Pacific$627.16M · 28.1%
Greater China$424.54M · 19.1%
CN$381.82M · 17.1%
Americas And Europe$298.09M · 13.4%
US$224.89M · 10.1%
Southeast Asia Pacific$132.00M · 5.9%
North Asia$70.63M · 3.2%
KR$68.86M · 3.1%
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing USANA HEALTH SCIENCES INC against the 5 most active filers in the same SIC group.